Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes (Q33630871)

28 July 2017

0 references

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes (English)

1 reference

28 July 2017

1 reference

J Glaspy

1

1 reference

28 July 2017

J Crawford

2

1 reference

28 July 2017

J Vansteenkiste

3

1 reference

28 July 2017

D Henry

4

1 reference

28 July 2017

S Rao

5

1 reference

28 July 2017

P Bowers

6

1 reference

28 July 2017

J A Berlin

7

1 reference

28 July 2017

D Tomita

8

1 reference

28 July 2017

K Bridges

9

1 reference

28 July 2017

H Ludwig

10

1 reference

28 July 2017

language of work or name

English

0 references

publication date

5 January 2010

1 reference

British Journal of Cancer

28 July 2017

published in

1 reference

28 July 2017

volume

102

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

301-315

1 reference

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Drug therapy for the management of cancer related fatigue

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Lack of functional erythropoietin receptors of cancer cell lines

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Medical and economic impact of anemia in hospitalized patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Perioperative blood transfusions and recurrence of colorectal cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Prevalence and outcomes of anemia in cancer: a systematic review of the literature

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Cancer and thromboembolic disease: pathogenic mechanisms

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Erythropoietin and erythropoietin receptor expression in human cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Meta-analysis: principles and procedures

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

The rationale for pathogen-inactivation treatment of blood components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Venous thromboembolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816662

Erythropoiesis-Stimulating Agents in the Treatment of Cancer-Associated Anemia

30 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605498

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia

21 January 2018

1 reference

12 December 2020

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

1 reference

12 December 2020

Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia

1 reference

12 December 2020

Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan A

1 reference

12 December 2020

Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group

1 reference

12 December 2020

Erythropoietin stimulates proliferation of human renal carcinoma cells

1 reference

12 December 2020

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

12 December 2020

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

1 reference

12 December 2020

Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy

1 reference

12 December 2020

Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study

1 reference

12 December 2020

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

12 December 2020

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

12 December 2020

Erythropoietin for anaemia in cancer patients

1 reference

12 December 2020

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo

1 reference

12 December 2020

Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response

1 reference

12 December 2020

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and N

1 reference

12 December 2020

Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Anti-Epo receptor antibodies do not predict Epo receptor expression

1 reference

12 December 2020

Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis

1 reference

12 December 2020

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

12 December 2020

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

1 reference

12 December 2020

Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies

1 reference

12 December 2020

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

12 December 2020

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

12 December 2020

Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)

1 reference

12 December 2020

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605498

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference